多年来,在我国先天性心脏病缺损手术治疗中,一直采用国外进口的封堵器,治疗费用十分昂贵。广东省心血管病研究所副所长、我国著名先天性心脏病专家张智伟教授,一直致力于先天性心脏病的研究。他作为主要发明人,参与研制了世界首创的生物陶瓷膜封堵器(Cera)。Cera陶瓷膜封堵技术自2006年陆续在海外开始临床实验,到目前为止,已有超过1000例成功植入的经验,同时顺利完成CE(欧盟注册),这标志着我国生产的心脏介入治疗器械首次进入国际市场。此研究已经列为国家“十五”科技攻关计划课题,其临床应用效果优于进口产品,降低了患者的治疗成本,提高了治愈率,有望在将来取代进口产品而广泛应用于国内临床。近日,张智伟教授在北京接受了本刊记者的采访,介绍了这项新技术研发的具体情况。 Over the years, surgical treatment of congenital heart defects in our country, has been using imported occluders, the treatment cost is very expensive. Guangdong Province Institute of Cardiovascular Diseases, deputy director of China’s famous congenital heart disease expert Professor Zhang Zhiwei, has been committed to the study of congenital heart disease. As a leading inventor, he was involved in the development of the world’s first Cera occluder. Cera ceramic membrane plugging technology has started clinical trials overseas since 2006, so far, more than 1000 cases of successful implantation have been completed and the CE (EU registration) has been successfully completed. This signifies that the cardiac interventional therapy devices For the first time into the international market. This research has been listed as national “fifteen ” scientific and technological project planning, its clinical application is better than imported products, reduce the cost of treatment of patients and improve the cure rate, is expected to replace the imported products in the future is widely used in clinical practice . Recently, Professor Zhang Zhiwei accepted an interview with our correspondents in Beijing and introduced the specific situation of this new technology research and development.